Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis

Molecular and Clinical Oncology
Taiyan GuoYing Luo

Abstract

Aberrant methylation of the breast cancer susceptibility gene 1 (BRCA1) promoter is a mechanism for its functional inactivation. It may potentially be used as a prognostic marker in studies for patients with breast cancer and plays an important role in tumorigenesis. Numerous studies have suggested that the methylation of the BRCA1 promoter is associated with the prognosis of breast cancer. However, the prognosis of BRCA1 promoter methylation in breast cancer patients of different ethnicities remains ambiguous. The present meta-analysis was performed to adjust and augment a previously published study, which estimated the correlations between promoter methylation of BRCA1 and the clinical outcomes of breast cancer patients. These results indicated that BRCA1 methylation was significantly correlated with a poor prognosis of breast cancer, particularly for Asian patients, but the correlation was over-estimated in the previous study. The combined hazard ratios (HRs) in the present study were 1.76 (1.15-2.68) and 1.97 (1.12-3.44) for univariate and multivariate analysis of overall survival, which were different from 2.02 (1.35-3.03) and 1.38 (1.04-1.84) in the previous study. For studies of disease-free survival, the univariate and ...Continue Reading

References

Jan 1, 1993·Statistical Methods in Medical Research·J L Fleiss
Jun 30, 1996·Statistics in Medicine·R DerSimonian
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Feb 12, 1998·Annals of Internal Medicine·J LauC H Schmid
Sep 4, 1998·Frontiers in Bioscience : a Journal and Virtual Library·J RussoI H Russo
Apr 6, 2000·Journal of the National Cancer Institute·M EstellerJ G Herman
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Jul 19, 2006·Breast Cancer Research : BCR·Valgerdur BirgisdottirJorunn E Eyfjord
Nov 30, 2006·Pharmacological Reviews·Karin Dahlman-WrightJan-Ake Gustafsson
Apr 22, 2008·International Journal of Epidemiology·Nikolaos A PatsopoulosJohn P A Ioannidis
Jun 4, 2008·Breast Cancer Research and Treatment·Xinran XuJia Chen
Dec 10, 2008·American Journal of Epidemiology·Leon BaxKarel G M Moons
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Feb 15, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y XuY Xie
Sep 13, 2013·Breast Cancer Research and Treatment·T IgnatovJ Bischoff
Nov 22, 2013·Breast Cancer Research and Treatment·Liang WuCheng Lu
Sep 2, 2014·Journal of Cancer Therapeutics & Research·Priyanka SharmaRoy A Jensen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.